TABLE 1.
Patient demographics and clinical characteristicsa
| PCR neg high | PCR neg low | PCR pos high | PCR pos low | ||
|---|---|---|---|---|---|
| CyTox (N = 110) | CyTox (N = 53) | CyTox (N = 23) | CyTox (N = 15) | P value | |
| Sex | 0.986 | ||||
| Female | 36 (32.7%) | 16 (30.2%) | 7 (30.4%) | 5 (33.3%) | |
| Male | 74 (67.3%) | 37 (69.8%) | 16 (69.6%) | 10 (66.7%) | |
| Race/ethnicity | 0.567 | ||||
| Asian | 7 (6.4%) | 3 (5.7%) | 4 (17.4%) | 1 (6.7%) | |
| Black | 14 (12.7%) | 5 (9.4%) | 0 (0.0%) | 2 (13.3%) | |
| Other/multiracial | 36 (32.7%) | 16 (30.2%) | 9 (39.1%) | 4 (26.7%) | |
| White | 53 (48.2%) | 29 (54.7%) | 10 (43.5%) | 8 (53.3%) | |
| Nosocomial, >48 h | 0.002 | ||||
| Community | 74 (67.3%) | 39 (73.6%) | 7 (30.4%) | 8 (53.3%) | |
| Nosocomial | 36 (32.7%) | 14 (26.4%) | 16 (69.6%) | 7 (46.7%) | |
| Length of stay (days) | 0.122 | ||||
| Mean (SD) | 20.56 (47.85) | 13.21 (13.95) | 36.43 (35.79) | 18.60 (16.85) | |
| Median (Q1, Q3) | 10.00 (2.00, 22.00) | 10.00 (2.00, 15.00) | 19.00 (10.00, 57.50) | 11.00 (7.50, 29.00) | |
| Mortality at 7 days | 0.128 | ||||
| Deceased | 13 (11.8%) | 4 (7.5%) | 6 (26.1%) | 3 (20.2%) | |
| Mortality at 30 days | 0.072 | ||||
| Deceased | 21 (19.1%) | 5 (9.4%) | 8 (34.8%) | 3 (20.0%) | |
| Mortality 1 year | 0.159 | ||||
| Deceased | 24 (21.8%) | 12 (22.6%) | 10 (43.5%) | 3 (20.0%) | |
| Source | 0.456 | ||||
| Blood | 54 (49.1%) | 20 (37.7%) | 9 (39.1%) | 8 (53.3%) | |
| Respiratory | 56 (50.9%) | 33 (62.3%) | 14 (60.9%) | 7 (46.7%) | |
| Age, years | 0.319 | ||||
| Mean (SD) | 53.51 (25.11) | 57.28 (23.99) | 55.70 (22.84) | 65.33 (17.14) | |
| Median (Q1, Q3) | 60.00 (39.00, 73.00) | 62.00 (46.00, 75.00) | 58.00 (36.50, 72.00) | 70.00 (57.50, 73.00) | |
| Charlson comorbidity index | 0.325 | ||||
| Mean (SD) | 3.45 (3.34) | 3.72 (3.40) | 2.39 (2.74) | 2.60 (3.33) | |
| Median (Q1, Q3) | 2.50 (1.00, 5.00) | 3.00 (1.00, 6.00) | 2.00 (0.00, 3.50) | 2.00 (0.00, 3.50) | |
| Comorbidities | |||||
| Cancer | 27 (24.5%) | 17 (32.1%) | 4 (17.4%) | 2 (13.3%) | 0.357 |
| Cerebrovascular disease | 34 (30.9%) | 17 (32.1%) | 6 (26.1%) | 2 (13.3%) | 0.514 |
| Congestive heart failure | 23 (20.9%) | 15 (28.3%) | 1 (4.3%) | 2 (13.3%) | 0.104 |
| Chronic pulmonary disease | 41 (37.3%) | 31 (58.5%) | 3 (13.0%) | 4 (26.7%) | 0.001 |
| Diabetes no complications | 37 (33.6%) | 21 (39.6%) | 7 (30.4%) | 7 (46.7%) | 0.655 |
| Diabetes with complications | 18 (16.4%) | 12 (22.6%) | 2 (8.7%) | 3 (20.0%) | 0.498 |
| Myocardial infarction | 25 (22.7%) | 13 (24.5%) | 4 (17.4%) | 4 (26.7%) | 0.897 |
| Mild liver disease | 12 (10.9%) | 3 (5.7%) | 5 (21.7%) | 2 (13.3%) | 0.226 |
| Mod/ severe liver disease | 4 (3.6%) | 2 (3.8%) | 3 (13.0%) | 0 (0.0%) | 0.180 |
| Peripheral vascular disease | 24 (21.8%) | 13 (24.5%) | 1 (4.3%) | 5 (33.3%) | 0.135 |
| Renal disease | 40 (36.4%) | 15 (28.3%) | 3 (13.0%) | 3 (20.0%) | 0.111 |
a
Patients were divided into four groups: (i) patients with a negative SARS-CoV-2 PCR, with S. aureus isolates that were high cytotoxicity, (ii) patients with a negative SARS-CoV-2 PCR, with S. aureus isolates that were low cytotoxicity, (iii) patients with a positive SARS-CoV-2 PCR, with S. aureus isolates that were high cytotoxicity, and (iv) patients with a positive SARS-CoV-2 PCR, with S. aureus isolates that were low cytotoxicity. CyTox = cytotoxicity. Demographics and clinical characteristics of each group are shown.